Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Research

Pharmaceutical

Science

Biotechnology

Antibody Drug Conjugate Agreement

More Like This

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors. (Graphic: Business Wire)

Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program